Abcuro Inc
Profile last edited on: 3/23/2021

Next generation of T-Cell targeted bio-therapeutics
Year Founded
2015
First SBIR Year
2019
Latest SBIR Award
2020
Program Status
Active

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

90 Bridge StreetSuite 100
Newton, MA 02458
   (617) 714-9759?
   corporate.contact@abcuro.com
   www.abcuro.com
Multiple Locations:   
Congressional District:   04
County:   Middlesex

Public Profile

A biopharmaceutical company, Acuro Inc.'s promising new target for cancer immunotherapy - KLRG1 - is part of the firm's effort to address development of a new generation of immuno-modulatory bio-therapeutics for treating both autoimmunity and cancer. The company uses proprietary analysis of transcriptome data from human disease to identify new approaches to target key compartments of the immune system. KLRG1 has recently emerged as an attractive target to restore anti-tumor immune function. An inhibitory receptor of T and NK cells, it functions to reduce the activity of highly differentiated immune cells by interacting with its ligands E/N cadherin. Abcuro has developed a blocking antibody directed toward KLRG1 that restores immune function. The firm is leveraging the systematic target validation and clinical insights gained by its founders to identify new targets - effectively, intensive use of bioinformatics enables interrogation of the transcriptome of human disease together with ex-vivo. validation in diseased tissue has uncovered new approaches to target key compartments of the immune system.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
---
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount Project Title
2020 2 NIH $295,317
Antibody Blockade of T Cell Activating Co-Inhibitory Receptor KLRG1 for Treatment of Melanoma

People

  Stefano Gulla -- Founder and CEO

  Steven A Greenberg -- Founder Chair, Medical Advisory Board

  Hugo Lemessurier -- Director, Abcuro Pty Ltd

  David Neafus -- CFO

  Evan Thompson -- COO and Founder

SBIR firms in the news

There are no news available.